



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

January 22, 2021

Austin Evers
American Oversight
1030 15th Street NW, Suite B255
Washington, District of Columbia 20005
Via email: foia@americanoversight.org

Dear Mr. Evers:

This letter is in final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of March 5, 2020, assigned #20-00813-FOIA, for:

All records reflecting communications (including emails, email attachments, text messages, messages on messaging platforms (such as Slack, GChat or Google Hangouts, Lync, Skype, or WhatsApp), telephone call logs, calendar invitations, calendar entries, meeting notices, meeting agendas, informational material, talking points, any handwritten or electronic notes taken during any oral communications, summaries of any oral communications, or other materials) of the officials specified below regarding decisions about testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.

Department of Health and Human Services (HHS)

- i. Alex Azar, Secretary
- ii. Robert Kadlec, Assistant Secretary for Preparedness and Response
- iii. Brett Giroir, Assistant Secretary for Health
- iv. Rich Bright, Director of the Biomedical Advanced Research and Development Authority

Food and Drug Administration (FDA)

- i. Stephen Hahn, Commissioner
- ii. Amy Abernethy, Principal Deputy Commissioner
- iii. Janet Woodcock, Director of the Center for Drug Evaluation and Research
- iv. Jeff Shuren, Director of the Center for Devices and Radiological Health

Centers for Disease Control and Prevention (CDC)

- i. Robert Redfield, Director
- ii. Anne Schuchat, Principal Deputy Director
- iii. Nancy Messonnier, Director, National Center for Immunization and

Respiratory Diseases

iv. Jay C. Butler, Deputy Director for Infectious Diseases

National Institutes of Health (NIH)

i. Francis Collins, Director

National Institute of Allergy and Infectious Disease (NIAID)

i. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases

Please provide all responsive records from January 20, 2020, through the date of the search.

On March 27, 2020, you clarified the scope of your request to:

With respect to 20-00813-FOIA, we seek any records reflecting communications regarding any of the documents found responsive to 20-00812-FOIA. For example, if a formal, final directive regarding coronavirus testing from Director Redfield was circulated by email, we seek that email, and any responses to it. Similarly, if a responsive directive or decision memorandum was announced at a meeting, we seek the meeting notice, agenda, and any notes. Again, we believe these records can reasonably be found by inquiries to the offices of the four officials identified.

We located 145 pages of responsive records (4 pages released in full; 30 pages disclosed in part; 44 pages withheld in full; 37 pages referred to the Department of Health and Human Services (HHS) and 30 pages referred to the United States Food and Drug Administration (FDA)). After a careful review of these pages, some information was withheld from release pursuant to 5 U.S.C. §552 Exemptions (b)(5) (Presidential Communication Privilege), (b)(5) and (b)(6).

EXEMPTION 5 - Presidential Communications Privilege (PCP)

Exemption 5 protects inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency. Exemption 5 therefore incorporates the privileges that protect materials from discovery in litigation, including the deliberative process, attorney work-product, and attorney-client privileges. Information withheld under this exemption was protected under the deliberative process and presidential communications privileges. The deliberative process privilege protects the decision-making process of government agencies. The deliberative process privilege protects materials that are both predecisional and deliberative. The information that have been withheld under the deliberative process privilege of Exemption 5 are both predecisional and deliberative, and do not represent formal or informal agency policies or decisions. Examples of information withheld include recommendations, comments, opinions. The presidential communications privilege protects documents solicited and received by the President or his immediate White House advisers who have broad and significant responsibility for investigating and formulating the advice to be given to the President.

EXEMPTION 5

Exemption 5 protects inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency. Exemption 5 therefore incorporates the privileges that protect materials from discovery in litigation, including the deliberative

process, attorney work-product, and attorney-client privileges. Information withheld under this exemption was protected under the deliberative process privilege. The deliberative process privilege protects the decision-making process of government agencies. The deliberative process privilege protects materials that are both predecisional and deliberative. The materials that have been withheld under the deliberative process privilege of Exemption 5 are both predecisional and deliberative, and do not contain or represent formal or informal agency policies or decisions. Examples of information withheld include staff opinions, comments, summaries and analysis.

EXEMPTION 6

Exemption 6 protects information in personnel and medical files and similar files when disclosure would constitute a clearly unwarranted invasion of personal privacy. The information that has been withheld under Exemption 6 consists of personal information, such as personal email addresses; cell phone numbers; bridge lines; and conference identification numbers. We have determined that the individuals to whom this information pertains has a substantial privacy interest in withholding it.

You may contact our FOIA Public Liaison at 770-488-6277 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal by writing to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, Suite 729H, Washington, D.C. 20201. You may also transmit your appeal via email to FOIARequest@psc.hhs.gov.

Please mark both your appeal letter and envelope “FOIA Appeal.” Your appeal must be postmarked or electronically transmitted by April 22, 2021.

Documents belonging to the Department of Health and Human Services were found in our search (37 pages). In accordance with the Department’s implementing regulations, CDC does not make decisions on the release or denial of other agencies’ documents. We have referred your request to the following agency for their release determination and direct reply to you:


Department of Health and Human Services (HHS)
Freedom of Information Officer
Hubert H. Humphrey Building, Room 729H
200 Independence Avenue, SW
Washington, DC 20201

Documents belonging to the Food and Drug Administration (FDA) were found in our search (30 pages). In accordance with the Department’s implementing regulations, CDC does not make decisions on the release or denial of other agencies’ documents. We have referred your request to the following agency for their release determination and direct reply to you:

Page 4 – Austin Evers

Food and Drug Administration (FDA)
Division of Freedom of Information, OES
U.S. Food & Drug Administration
2630 Fishers Lane, Room 1035
Rockville, Maryland 20857

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized flourish at the end.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

Enclosures

20-00813-FOIA

From: Richard Siegel
Sent: 28 Jan 2020 21:24:18 -0800
To: Cho, Sam;Redd, Stephen (CDC/DDPHSIS/OD);Redfield, Robert R. (CDC/OD);Bornstein, Josh (CDC/OCOO/OSSAM);mike_spahn@murray.senate.gov;connor.stubbs@mail.house.gov
Cc: jdeleon@seattletimes.com
Subject: Re: [EXTERNAL] Corona Virus - Shortsighted Decisions

Sam,

Thanks for your speedy response.

It seems that the CDC is now including SEATAC in its expanded screening program for Corona virus for all flights from China.

My concern now is for **connecting flights** from other Asian countries that often include Chinese nationals on flights from Taiwan, Korea, Japan and other and other countries.

I will copy this email exchange to the CDC ,Senator Patty Murray, Representative Adam Smith/Connor Stubbs.

Thanks again.

Best,

— Rich Siegel

On Jan 27, 2020, at 10:34 PM, Cho, Sam <Cho.S@portseattle.org> wrote:

Richard,

Thanks for reaching out to us and expressing your concerns regarding Corona Virus screenings.

I share your concerns regarding screenings. I highly encourage you to reach out to CDC directly to articulate your concerns. Unfortunately, we as port commissioners have no jurisdiction over how CDC and Customs and Border Control conduct screenings at the airport. This is all conducted in their space at the airport. We only receive periodic updates.

I also encourage you to reach out to our congressional delegation and request that they pressure these federal agencies to step-up screenings.

Thanks,
Sam

-----Original Message-----

From: Richard Siegel (b)(6)

Sent: Monday, January 27, 2020 10:14 PM

To: Bowman, Stephanie <Bowman.S@portseattle.org>; Calkins, Ryan <Calkins.R@portseattle.org>; Cho, Sam <Cho.S@portseattle.org>; Felleman, Fred <Felleman.F@portseattle.org>; Pritchard, Aaron <Pritchard.A@portseattle.org>; Steinbrueck, Peter <Steinbrueck.P@portseattle.org>

Cc: jdeleon@seattletimes.com

Subject: [EXTERNAL] Corona Virus - Shortsighted Decisions

WARNING: This is an external email. Do not click on links or open attachments unless you recognize the sender and expect the content of this email to be safe.

Ladies and Gentleman:

You should seriously reconsider your decision to not conduct Corona Virus screening at SEATAC International Airport.

There are additional outbreaks of the virus in China in other cities with direct flights to Seattle not just from Wuhan. We have all seen the outcomes of shortsighted decisions before. Usually they begin with phrases such as “If i had known”, and “Why did we not act earlier”., “We are very sorry but ...”.

Now is the time to err on the side of caution and change your screening process.

Act now and you will help prevent the spread of Corona Virus and possibly save lives.

Sincerely,

Richard Siegel
Bellevue, WA

(b)(6)

From: Richard Siegel
Sent: 29 Jan 2020 18:13:09 -0800
To: Cho, Sam;Redd, Stephen (CDC/DDPHSIS/OD);Redfield, Robert R. (CDC/OD);Bornstein, Josh (CDC/OCOO/OSSAM);Spahn, Mike (Murray);connor.stubbs@mail.house.gov;david.postman@gov.wa.gov
Cc: jdeleon@seattletimes.com
Subject: Re: [EXTERNAL] Corona Virus - Shortsighted Decisions

Ladies and Gentlemen of the Port of Seattle, the Centers for Disease Control, and the Office of the Governor of the State of Washington,

I have written to the Port of Seattle and received speedy, informative and rational feedback from Port of Seattle Commissioners. I also had an informative conversation with Representative Adam Smith's staff (Connor Stubbs).

Thank all of your emails and discussion. You do value public opinion and engagement!

Again, i am including the CDC in this email — and for the first time -- Governor Jay InIslee's office through his Chief of Staff.

I understand that Jay has recommend temperature and history history screens for flights coming to SEATAC from China.

BOAC has apparently stopped all flights to and from China.

GOOGLE is planning to close all of its China offices on a temporary basis.

It appears that our Governor and the CDC have a difference of opinion regarding screening at SEATAC. i applaud his insight. I strongly believe this is the immediate correct direction for the CDC to take.

I am not happy with the Influenza data comparison from the CDC. The incidences of death are annual and not from the early weeks of the start of the Influenza season. Also i would suspect that more cases showed up in cities and states around the country with difference political, cultural, or religious perspectives. More cases most likely occurred in densely populated cities too.

Frankly, I think the Governor and the Port of Seattle should profit all flights from China and from cities in Asia that have connect flights where Chinese nationals may be entering from other countries.

it seems the CDC and the Governor's office may be at odds in what to do now:

Erring on the side of caution — closing the airport to all incoming and outgoing flights from Asian cities is not a blunt instrument if it is used temporarily as an early attempt to reduce or slow down the rapid spread of this corona virus that the world is facing now.

Best,

--Rich Siegel

(b)(6)

On Jan 28, 2020, at 9:24 PM, Richard Siegel (b)(6) wrote:

Sam,

Thanks for your speedy response.

It seems that the CDC is now including SEATAC in its expanded screening program for Corona virus for all flights from China.

My concern now is for **connecting flights** from other Asian countries that often include Chinese nationals on flights from Taiwan, Korea, Japan and other and other countries.

I will copy this email exchange to the CDC ,Senator Patty Murray, Representative Adam Smith/Connor Stubbs.

Thanks again.

Best,

— Rich Siegel

On Jan 27, 2020, at 10:34 PM, Cho, Sam
<Cho.S@portseattle.org> wrote:

Richard,

Thanks for reaching out to us and expressing your concerns regarding Corona Virus screenings.

I share your concerns regarding screenings. I highly encourage

you to reach out to CDC directly to articulate your concerns. Unfortunately, we as port commissioners have no jurisdiction over how CDC and Customs and Border Control conduct screenings at the airport. This is all conducted in their space at the airport. We only receive periodic updates.

I also encourage you to reach out to our congressional delegation and request that they pressure these federal agencies to step-up screenings.

Thanks,
Sam

-----Original Message-----

From: Richard Siegel (b)(6)
Sent: Monday, January 27, 2020 10:14 PM
To: Bowman, Stephanie <[Bowman.S@portseattle.org](mailto: Bowman.S@portseattle.org)>; Calkins, Ryan <[Calkins.R@portseattle.org](mailto: Calkins.R@portseattle.org)>; Cho, Sam <[Cho.S@portseattle.org](mailto: Cho.S@portseattle.org)>; Felleman, Fred <[Felleman.F@portseattle.org](mailto: Felleman.F@portseattle.org)>; Pritchard, Aaron <[Pritchard.A@portseattle.org](mailto: Pritchard.A@portseattle.org)>; Steinbrueck, Peter <[Steinbrueck.P@portseattle.org](mailto: Steinbrueck.P@portseattle.org)>
Cc: [jdeleon@seattletimes.com](mailto: jdeleon@seattletimes.com)
Subject: [EXTERNAL] Corona Virus - Shortsighted Decisions

WARNING: This is an external email. Do not click on links or open attachments unless you recognize the sender and expect the content of this email to be safe.

Ladies and Gentleman:

You should seriously reconsider your decision to not conduct Corona Virus screening at SEATAC International Airport.

There are additional outbreaks of the virus in China in other cities with direct flights to Seattle not just from Wuhan. We have all seen the outcomes of shortsighted decisions before.

Usually they begin with phrases such as “If I had known”, and “Why did we not act earlier”., “We are very sorry but ...”.

Now is the time to err on the side of caution and change your screening process.

Act now and you will help prevent the spread of Corona Virus and possibly save lives.

Sincerely,

Richard Siegel

Bellevue, WA

(b)(6)

From: Berger, Sherri (CDC/OCOO/OD)
Sent: 30 Jan 2020 02:55:35 +0000
To: Butler, Jay C. (CDC/DDID/OD)
Subject: Fwd: [EXTERNAL] Corona Virus - Shortsighted Decisions

I'm not sure what this is

From: Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>
Sent: Wednesday, January 29, 2020 9:15 PM
To: Berger, Sherri (CDC/OCOO/OD)
Subject: FW: [EXTERNAL] Corona Virus - Shortsighted Decisions

More. Just sent to you – not sure if anyone else needs.

From: Richard Siegel (b)(6)
Sent: Wednesday, January 29, 2020 9:13 PM
To: Cho, Sam <Cho.S@portseattle.org>; Redd, Stephen (CDC/DDPHSIS/OD) <scr1@cdc.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>; Spahn, Mike (Murray) <mike_spahn@murray.senate.gov>; connor.stubbs@mail.house.gov; david.postman@gov.wa.gov
Cc: jdeleon@seattletimes.com
Subject: Re: [EXTERNAL] Corona Virus - Shortsighted Decisions

Ladies and Gentlemen of the Port of Seattle, the Centers for Disease Control, and the Office of the Governor of the State of Washington,

I have written to the Port of Seattle and received speedy, informative and rational feedback from Port of Seattle Commissioners. I also had an informative conversation with Representative Adam Smith's staff (Connor Stubbs).

Thank all of your emails and discussion. You do value public opinion and engagement!

Again, i am including the CDC in this email — and for the first time -- Governor Jay Inslee's office through his Chief of Staff.

I understand that Jay has recommend temperature and history history screens for flights coming to SEATAC from China.

BOAC has apparently stopped all flights to and from China.

GOOGLE is planning to close all of its China offices on a temporary basis.

It appears that our Governor and the CDC have a difference of opinion regarding screening at SEATAC. i applaud his insight. I strongly believe this is the immediate correct direction for the CDC to take.

I am not happy with the Influenza data comparison from the CDC. The incidences of death are annual and not from the early weeks of the start of the Influenza season. Also i would suspect that more cases showed up in cities and states around the country with difference political, cultural, or religious perspectives. More cases most likely occurred in densely populated cities too.

Frankly, I think the Governor and the Port of Seattle should profit all flights from China and from cities in Asia that have connect flights where Chinese nationals may be entering from other countries.

it seems the CDC and the Governor's office may be at odds in what to do now:

Erring on the side of caution — closing the airport to all incoming and outgoing flights from Asian cities is not a blunt instrument if it is used temporarily as an early attempt to reduce or slow down the rapid spread of this corona virus that the world is facing now.

Best,

--Rich Siegel

(b)(6)

On Jan 28, 2020, at 9:24 PM, Richard Siegel (b)(6) wrote:

Sam,

Thanks for your speedy response.

It seems that the CDC is now including SEATAC in its expanded screening program for Corona virus for all flights from China.

My concern now is for **connecting flights** from other Asian countries that often include Chinese nationals on flights from Taiwan, Korea, japan and other and other countries.

I will copy this email exchange to the CDC ,Senator Patty Murray, Representative Adam Smith/Connor Stubbs.

Thanks again.

Best,

— Rich Siegel

On Jan 27, 2020, at 10:34 PM, Cho, Sam <Cho.S@portseattle.org> wrote:

Richard,

Thanks for reaching out to us and expressing your concerns regarding Corona Virus screenings.

I share your concerns regarding screenings. I highly encourage you to reach out to CDC directly to articulate your concerns. Unfortunately, we as port commissioners have no jurisdiction over how CDC and Customs and Border Control conduct screenings at the airport. This is all conducted in their space at the airport. We only receive periodic updates.

I also encourage you to reach out to our congressional delegation and request that they pressure these federal agencies to step-up screenings.

Thanks,
Sam

-----Original Message-----

From: Richard Siegel (b)(6)
Sent: Monday, January 27, 2020 10:14 PM
To: Bowman, Stephanie <Bowman.S@portseattle.org>; Calkins, Ryan <Calkins.R@portseattle.org>; Cho, Sam <Cho.S@portseattle.org>; Felleman, Fred <Felleman.F@portseattle.org>; Pritchard, Aaron <Pritchard.A@portseattle.org>; Steinbrueck, Peter <Steinbrueck.P@portseattle.org>
Cc: jdeleon@seattletimes.com
Subject: [EXTERNAL] Corona Virus - Shortsighted Decisions

WARNING: This is an external email. Do not click on links or open attachments unless you recognize the sender and expect the content of this email to be safe.

Ladies and Gentleman:

You should seriously reconsider your decision to not conduct Corona Virus screening at SEATAC International Airport.

There are additional outbreaks of the virus in China in other cities with direct flights to Seattle not just from Wuhan. We have all seen the outcomes of shortsighted decisions before. Usually they begin with phrases such as “If I had known”, and “Why did we not act earlier” ., “We are very sorry but ...”.

Now is the time to err on the side of caution and change your screening process.

Act now and you will help prevent the spread of Corona Virus and possibly save lives.

Sincerely,

Richard Siegel
Bellevue, WA

(b)(6)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

From: Redd, Stephen (CDC/DDPHSIS/OD)
Sent: 10 Mar 2020 14:21:04 +0000
To: Schuchat, Anne MD (CDC/OD)
Subject: Re: [redacted] b(5) (PCP)

[redacted] (b)(5)

Stephen C. Redd, MD
RADM, USPHS

[redacted] b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Sent: 11 Mar 2020 19:06:53 +0000
To: Berger, Sherri (CDC/OCOO/OD);Schuchat, Anne MD (CDC/OD);Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
Cc: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID)
Subject: Re: CO open first drive-up testing center at State Lab in Lowry & Utah COVID-19 Community Task Force recommends establishment of satellite COVID-19 testing sites

Adding Dana.

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Wednesday, March 11, 2020 3:05:30 PM
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Subject: FW: CO open first drive-up testing center at State Lab in Lowry & Utah COVID-19 Community Task Force recommends establishment of satellite COVID-19 testing sites

Who has this one? Thanks

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD)
Sent: 16 Mar 2020 17:49:45 +0000
To: Schuchat, Anne MD (CDC/OD);Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD)
Subject: RE: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA) - (b)(5)
(b)(5)

(b)(5)

Steve Monroe, PhD
Director, Office of Laboratory Science and Safety
CDC

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Monday, March 16, 2020 1:16 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: FW: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Importance: High

From: Hoffmann, Lauren (CDC/OD/OCS) <cpf5@cdc.gov>
Sent: Monday, March 16, 2020 12:37 PM
To: CDC IMS JIC Emergency Clearance-2 <eocjicclear2@cdc.gov>; Ford, Kenya S. (CDC/OCOO/OGC) <kdf6@cdc.gov>; Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Cc: CDC Review Clear Coordinator <rcc@cdc.gov>; CDC Regulations <cdcregulations@cdc.gov>; Clark, Cynthia K. (CDC/OD/OCS) <cfc8@cdc.gov>; Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Campbell, Amanda (CDC/OD/OCS) <ons3@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>
Subject: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Importance: High

JIC Clearance: Attached via HHS is an urgent review request for FDA testing guidance. **Response due to me at 1:50 PM.** This is for immediate effect and late responses may not be accepted. Please route to appropriate IMS taskforce and leadership

(b)(5)

Lauren

Lauren Hoffmann, MA, BS | Lead Public Health Analyst/Senior Issues Manager, Division of Issues Management, Analysis and Coordination (IMAC) | Office of Chief of Staff | Office of the Director | Centers for Disease Control and Prevention
1600 Clifton Road, NE, Mail Stop H21-10, Atlanta, GA 30329-4027 | Office: 404-639-7126 | Mobile: (b)(6) | E-mail: lhoffmann@cdc.gov.

From: Schuchat, Anne MD (CDC/OD)
Sent: 16 Mar 2020 17:52:08 +0000
To: Hoffmann, Lauren (CDC/OD/OCS)
Subject: FW: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA) - (b)(5)
(b)(5)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Monday, March 16, 2020 1:50 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: RE: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA) - (b)(5)

(b)(5)

Steve Monroe, PhD
Director, Office of Laboratory Science and Safety
CDC

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Monday, March 16, 2020 1:16 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: FW: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Importance: High

From: Hoffmann, Lauren (CDC/OD/OCS) <cpf5@cdc.gov>
Sent: Monday, March 16, 2020 12:37 PM
To: CDC IMS JIC Emergency Clearance-2 <eocjicclear2@cdc.gov>; Ford, Kenya S. (CDC/OCOO/OGC) <kdf6@cdc.gov>; Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Cc: CDC Review Clear Coordinator <rcc@cdc.gov>; CDC Regulations <cdcregulations@cdc.gov>; Clark, Cynthia K. (CDC/OD/OCS) <cfc8@cdc.gov>; Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Campbell, Amanda (CDC/OD/OCS) <ons3@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>
Subject: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Importance: High

JIC Clearance: Attached via HHS is an urgent review request for FDA testing guidance. **Response due to me at 1:50 PM.** This is for immediate effect and late responses may not be accepted. Please route to appropriate IMS taskforce and leadership

(b)(5)

Lauren

Lauren Hoffmann, MA, BS | Lead Public Health Analyst/Senior Issues Manager, Division of Issues Management, Analysis and Coordination (IMAC) | Office of Chief of Staff | Office of the Director | Centers for Disease Control and Prevention
1600 Clifton Road, NE, Mail Stop H21-10, Atlanta, GA 30329-4027 | Office: 404-639-7126 | Mobile: (b)(6) | E-mail: lhoffmann@cdc.gov.

From: Hoffmann, Lauren (CDC/OD/OCS)
Sent: 16 Mar 2020 17:54:21 +0000
To: Schuchat, Anne MD (CDC/OD)
Subject: RE: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA) - (b)(5)
(b)(5)

Thank you.

Lauren Hoffmann, MA, BS | Lead Public Health Analyst/Senior Issues Manager, Division of Issues Management, Analysis and Coordination (IMAC) | Office of Chief of Staff | Office of the Director | Centers for Disease Control and Prevention
1600 Clifton Road, NE, Mail Stop H21-10, Atlanta, GA 30329-4027 | Office: 404-639-7126 | Mobile: (b)(6) | E-mail: lhoffmann@cdc.gov.

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Monday, March 16, 2020 1:52 PM
To: Hoffmann, Lauren (CDC/OD/OCS) <cpf5@cdc.gov>
Subject: FW: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA) - (b)(5)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Monday, March 16, 2020 1:50 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: RE: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA) - (b)(5)

(b)(5)

Steve Monroe, PhD
Director, Office of Laboratory Science and Safety
CDC

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Monday, March 16, 2020 1:16 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: FW: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Importance: High

From: Hoffmann, Lauren (CDC/OD/OCS) <cpf5@cdc.gov>
Sent: Monday, March 16, 2020 12:37 PM
To: CDC IMS JIC Emergency Clearance-2 <eocjicclear2@cdc.gov>; Ford, Kenya S. (CDC/OCOO/OGC) <kdf6@cdc.gov>; Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Cc: CDC Review Clear Coordinator <rcc@cdc.gov>; CDC Regulations <cdcregulations@cdc.gov>; Clark,

Cynthia K. (CDC/OD/OCS) <cfc8@cdc.gov>; Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Campbell, Amanda (CDC/OD/OCS) <ons3@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>
Subject: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)

Importance: High

JIC Clearance: Attached via HHS is an urgent review request for FDA testing guidance. **Response due to me at 1:50 PM.** This is for immediate effect and late responses may not be accepted. Please route to appropriate IMS taskforce and leadership

(b)(5)

Lauren

Lauren Hoffmann, MA, BS | Lead Public Health Analyst/Senior Issues Manager, Division of Issues Management, Analysis and Coordination (IMAC) | Office of Chief of Staff | Office of the Director | Centers for Disease Control and Prevention
1600 Clifton Road, NE, Mail Stop H21-10, Atlanta, GA 30329-4027 | Office: 404-639-7126 | Mobile: (b)(6) | E-mail: lhoffmann@cdc.gov.

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD)
Sent: 31 Mar 2020 22:55:33 +0000
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD);Limbago, Brandi (CDC/DDID/NCIRD/OD);Armstrong, Gregory (CDC/DDID/NCEZID/OD);Bresee, Joseph (CDC/DDID/NCIRD/ID)
Cc: Schuchat, Anne MD (CDC/OD);Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID);Dauphin, Leslie (CDC/DDPHSS/OLSS/OD);Monroe, Steve (CDC/DDPHSS/OLSS/OD)

Subject: [redacted] (b)(5)
[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

Steve

Steve Monroe, PhD
Associate Director for Laboratory Science and Safety
Director, Office of Laboratory Science and Safety
Centers for Disease Control and Prevention (CDC)
[+1-404-639-2391](tel:+14046392391) (direct)
[\[redacted\]](tel:[redacted]) (mobile)
smonroe@cdc.gov
EA: Ms. Ja'Lisa Ayewa / JAyewa@cdc.gov / +1-404-498-1694



From: Kuhnert-Tallman, Wendi (CDC/DDID/OD)
Sent: 31 Mar 2020 23:52:39 +0000
To: Monroe, Steve (CDC/DDPHSS/OLSS/OD);Limbago, Brandi (CDC/DDID/NCIRD/OD);Armstrong, Gregory (CDC/DDID/NCEZID/OD);Bresee, Joseph (CDC/DDID/NCIRD/ID)
Cc: Schuchat, Anne MD (CDC/OD);Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID);Dauphin, Leslie (CDC/DDPHSS/OLSS/OD);Kuhnert-Tallman, Wendi (CDC/DDID/OD)
Subject: RE: [redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

Wendi

Wendi Kuhnert-Tallman
phone [redacted] (b)(6)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Tuesday, March 31, 2020 6:56 PM
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: [redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

(b)(5)

Steve

Steve Monroe, PhD
Associate Director for Laboratory Science and Safety
Director, Office of Laboratory Science and Safety
Centers for Disease Control and Prevention (CDC)

[+1-404-639-2391](tel:+14046392391) (direct)

[\(b\)\(6\)](#) (mobile)

smonroe@cdc.gov

EA: Ms. Ja'Lisa Ayewa / JAyewa@cdc.gov / +1-404-498-1694

OLSS Office of Laboratory
Science and Safety

Strengthening the culture of laboratory science and safety at CDC

An ISO 9001:2015 certified organization

From: Schuchat, Anne MD (CDC/OD)
Sent: 1 Apr 2020 00:12:34 +0000
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD)
Subject: RE (b)(5)

(b)(5)

Thanks Wendi!

From: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>
Sent: Tuesday, March 31, 2020 7:53 PM
To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>
Subject: RE (b)(5)

(b)(5)

(b)(5)

(b)(5)

(b)(5)

Wendi

Wendi Kuhnert-Tallman
phone (b)(6)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Tuesday, March 31, 2020 6:56 PM
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>

Subject:

(b)(5)

(b)(5)

(b)(5)

(b)(5)

Steve

Steve Monroe, PhD

Associate Director for Laboratory Science and Safety

Director, Office of Laboratory Science and Safety

Centers for Disease Control and Prevention (CDC)

[+1-404-639-2391](tel:+14046392391) (direct)

(b)(6) (mobile)

smonroe@cdc.gov

EA: Ms. Ja'Lisa Ayewa / JAyewa@cdc.gov / +1-404-498-1694

OLSS Office of Laboratory
Science and Safety

Strengthening the culture of laboratory science and safety at CDC

An ISO 9001:2015 certified organization

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD)
Sent: 1 Apr 2020 00:57:51 +0000
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD);Limbago, Brandi (CDC/DDID/NCIRD/OD);Armstrong, Gregory (CDC/DDID/NCEZID/OD);Bresee, Joseph (CDC/DDID/NCIRD/ID)
Cc: Schuchat, Anne MD (CDC/OD);Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID);Dauphin, Leslie (CDC/DDPHSS/OLSS/OD);Monroe, Steve (CDC/DDPHSS/OLSS/OD)
Subject: RE [redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

Steve Monroe, PhD
Associate Director for Laboratory Science and Safety, CDC

From: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>
Sent: Tuesday, March 31, 2020 7:53 PM
To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>

Subject: RE [redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

Wendi

Wendi Kuhnert-Tallman
phone (b)(6)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Tuesday, March 31, 2020 6:56 PM
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>

Subject (b)(5)

(b)(5)

(b)(5)

(b)(5)

Steve

Steve Monroe, PhD
Associate Director for Laboratory Science and Safety
Director, Office of Laboratory Science and Safety
Centers for Disease Control and Prevention (CDC)
[+1-404-639-2391](tel:+14046392391) (direct)
(b)(6) (mobile)
smonroe@cdc.gov
EA: Ms. Ja'Lisa Ayewa / JAyewa@cdc.gov / +1-404-498-1694

OLSS Office of Laboratory
Science and Safety

Strengthening the culture of laboratory science and safety at CDC

An ISO 9001:2015 certified organization

From: Kuhnert-Tallman, Wendi (CDC/DDID/OD)
Sent: 1 Apr 2020 14:17:24 +0000
To: Butler, Jay C. (CDC/DDID/OD)
Subject: FW: [REDACTED] (b)(5)

[REDACTED] (b)(5)

[REDACTED] (b)(5)

Thanks, wendi

Wendi Kuhnert-Tallman
phone [REDACTED] (b)(6)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Tuesday, March 31, 2020 8:58 PM
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: RE: [REDACTED] (b)(5)

[REDACTED] (b)(5)

[REDACTED] (b)(5)

[REDACTED] (b)(5)

Steve Monroe, PhD
Associate Director for Laboratory Science and Safety, CDC

From: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>
Sent: Tuesday, March 31, 2020 7:53 PM
To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>
Subject: RE: [REDACTED] (b)(5)

[REDACTED] (b)(5)

[REDACTED] (b)(5)

(b)(5)

(b)(5)

(b)(5)

Wendi

Wendi Kuhnert-Tallman
phone - (b)(6)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Tuesday, March 31, 2020 6:56 PM
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Limbago, Brandi (CDC/DDID/NCIRD/OD) <bbl7@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Bresee, Joseph (CDC/DDID/NCIRD/ID) <jsb6@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Dauphin, Leslie (CDC/DDPHSS/OLSS/OD) <lvh7@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>

Subject: (b)(5)

(b)(5)

(b)(5)

(b)(5)

Steve

Steve Monroe, PhD
Associate Director for Laboratory Science and Safety
Director, Office of Laboratory Science and Safety
Centers for Disease Control and Prevention (CDC)

[+1-404-639-2391](tel:+14046392391) (direct)

(b)(6) (mobile)

smonroe@cdc.gov

EA: Ms. Ja'Lisa Ayewa / JAyewa@cdc.gov / +1-404-498-1694

OLSS Office of Laboratory
Science and Safety

Strengthening the culture of laboratory science and safety at CDC

An ISO 9001:2015 certified organization

From: Kropaczek Veronica
Sent: 10 Apr 2020 16:36:17 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Pantoja Sito; Martinez Bob, IP; Richard L. Trumka (rtrumka@afcio.org); Stephen Cotton (cotton_stephen@itf.org.uk); Nick Calio (ncalio@airlines.org); ebusby@aar.org
Subject: COVID-19 Testing for Essential Transportation Workers
Attachments: IAM letter to CDC re COVID-19 Testing 4-10-2020.pdf


Director Redfield,

Please see the attached correspondence in the above-captioned matter. A hard copy will not follow unless requested.

Sincerely,

Veronica Koloditch Kropaczek
Confidential Secretary to General Vice President Sito Pantoja
Transportation Department
International Association of Machinists & Aerospace Workers (IAM&AW)
vkoloditch-kropaczek@iamaw.org
Phone: (b)(6)
Fax: (301) 967-4561
9000 Machinists Place
Upper Marlboro, MD 20772

Notice: This message is intended for the addressee only and may contain privileged and/or confidential information. Use or dissemination by anyone other than the intended recipient is strictly prohibited.



April 10, 2020

Re: COVID-19 Testing for Essential
Transportation Workers

Via electronic mail

Robert Redfield, MD
Director of the Centers for Disease Control
and Prevention
1600 Clifton Rd. NE
Atlanta, GA 30333
olx1@cdc.gov

Dear Director Redfield:

I write you this letter today to express my grave concern regarding the lack of access to coronavirus testing for airline and rail workers. As you know, airline and rail employees have been deemed essential workers and must show up to work each and every day to ensure that critical medical supplies, essential consumer goods, US mail, and other essential workers and first responders are transported to where they are needed. Airline workers, in particular, are also responsible for repatriating approximately 50,000 US citizens from all corners of the globe. Air, rail, and transit workers are saving lives and entire communities.

While transportation workers have answered the call in the most patriotic and caring ways possible, they are also contracting the novel coronavirus at alarming rates. Sadly, some of these brave workers have died, others are currently fighting for their lives. The IAM has worked diligently with the carriers in which we have members and they have admirably instituted, and will institute, many safety and health procedures that have undoubtedly reduced the risk of IAM members contracting the novel coronavirus at work. However, we are very concerned that the lack of access to coronavirus testing is placing all essential transportation workers at increased risk of getting sick and then spreading the virus.

Under current federal testing guidelines, airline and rail workers cannot be tested for COVID-19 unless they are symptomatic. The CDC, furthermore, has warned that 25 percent of individuals who have contracted the novel coronavirus are asymptomatic. This creates a very dangerous situation for essential workers who must report to work, especially when that work requires interaction with the traveling public. Even with vigilant social distancing and appropriate PPE at the workplace, which is lacking across the country, having workers who have contracted the novel coronavirus and are asymptomatic or pre-symptomatic places them, their families, co-workers and the traveling public at risk. These essential employees could be infecting travelers who will then spread the virus across the country. This also increases the risk that an increasing

Robert Redfield, MD

April 10, 2020

Page 2

amount of essential workers will get sick and not be able to perform their duties during this precarious time.


We request that all essential transportation workers, whether they work at the airport or on the nation's railroads and transit systems, have the right to obtain a coronavirus test even if they have no symptoms. By having this information, these heroic workers would be able to protect themselves, their families, and their co-workers and help stop the spread of the virus.

We owe these essential workers nothing less and we look forward to your prompt response.

Fraternally,



Sito Pantoja
GENERAL VICE PRESIDENT



Dave Supplee
PRESIDENT/DIRECTING
GENERAL CHAIRMAN, IAM DL 142



Mike Klemm
PRESIDENT/DIRECTING
GENERAL CHAIRMAN, IAM DL 141



Mike Perry
PRESIDENT/DIRECTING
GENERAL CHAIRMAN, IAM DL 19

cc: Robert Martinez, Jr., International President, IAM
Richard Trumka, President, AFL-CIO
Steven Cotton, General Secretary, International Transport Workers Federation
Nicholas E. Calio, President and CEO, Airlines for America
Ian Jefferies, CEO and President, Association of American Railroads

From: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID)
Sent: 15 Apr 2020 20:27:04 +0000
To: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID);Schuchat, Anne MD (CDC/OD);McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP)
Subject: updates and decisions

Join Skype Meeting

Trouble Joining? [Try Skype Web App](#)

Join by phone

(b)(6)	(Atlanta Dial-in Conference Region)
(b)(6)	(Atlanta Dial-in Conference Region)

English (United States)
English (United States)

[Find a local number](#)

Conference ID: (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

From: Redfield, Robert R. (CDC/OD)
Sent: 20 Apr 2020 02:12:11 +0000
Subject: Fwd: Frequently Asked COVID-19 Testing Questions from States

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

b(5) (PCP)

From: Audio Conference Notification
Sent: 21 Apr 2020 16:48:02 +0000
To: Redfield, Robert R. (CDC/OD)
Subject: Confirmation: Technical Assistance Call with State & Community Leaders on Expanding COVID-19 Testing on April 21, 2020 at 1:30 PM Eastern Time

Dear Robert,

Here is your personalized dial-in information for the audio conference **Technical Assistance Call with State & Community Leaders on Expanding COVID-19 Testing**.

The conference begins at 1:30 PM Eastern Time on April 21, 2020; you may join 10 minutes prior.

Dial-in: (b)(6) or (b)(6) or [Find an Alternate Number](#)

Access Code: (b)(6)

Attendee ID: (b)(6)

(These instructions are unique to you, do not share)

[Add to your calendar](#)

Need assistance with your audio? Please dial (b)(6)



Subject: FDA FOIA 2021-536
Date: Monday, February 22, 2021 at 4:47:49 PM Eastern Standard Time
From: Kotler, Sarah
To: FOIA
CC: Russ, Wilson
Attachments: 20-00813 (Evers) REFER TO FDA_Redacted.pdf

EXTERNAL SENDER

Dear Requester,

Please find attached records that were referred to FDA by CDC. We are withholding portions of the records under Exemption 5 of the FOIA.

You have the right to appeal this determination. By filing an appeal, you preserve your rights under FOIA and give the agency a chance to review and reconsider your request and the agency's decision. Your appeal must be mailed within 90 days from the date of this response, to: **Director, Office of the Executive Secretariat, US Food & Drug Administration, 5630 Fishers Lane, Room 1050, Rockville, MD 20857, E-mail: FDAFOIA@fda.hhs.gov**. Please clearly mark both the envelope and your letter or e-mail "FDA Freedom of Information Act Appeal."

If you would like to discuss our response before filing an appeal to attempt to resolve your dispute without going through the appeals process, please contact me at 301-796-8976 or Sarah.Kotler@fda.hhs.gov. You may also contact the FDA FOIA Public Liaison for assistance at:

Office of the Executive Secretariat
US Food & Drug Administration
5630 Fishers Lane, Room 1050
Rockville, MD 20857

E-mail: FDAFOIA@fda.hhs.gov

If you are unable to resolve your FOIA dispute through our FOIA Public Liaison, the Office of Government Information Services (OGIS), the Federal FOIA Ombudsman's office, offers mediation services to help resolve disputes between FOIA requesters and Federal agencies. The contact information for OGIS is:

Office of Government Information Services
National Archives and Records Administration
8601 Adelphi Road—OGIS
College Park, MD 20740-6001
Telephone: 202-741-5770
Toll-Free: 1-877-684-6448

E-mail: ogis@nara.gov

Fax: 202-741-5769

Sincerely,

Sarah B. Kotler, J.D.

Director, Division of Freedom of Information

US FDA

301-796-8976

From: Hoffmann, Lauren (CDC/OD/OCS)
Sent: 16 Mar 2020 16:36:45 +0000
To: CDC IMS JIC Emergency Clearance-2;Ford, Kenya S. (CDC/OCOO/OGC);Tress, Deborah W. (CDC/OCOO/OGC)
Cc: CDC Review Clear Coordinator;CDC Regulations;Clark, Cynthia K. (CDC/OD/OCS);Caudwell, Kerry M. (CDC/OD/OCS);CDC IMS JIC OADC LNO -2;CDC IMS 2019 NCOV Response Policy;Schuchat, Anne MD (CDC/OD);Campbell, Amanda (CDC/OD/OCS);McGowan, Robert (Kyle) (CDC/OD/OCS)
Subject: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Attachments: 20010-IIE-COVID-19-2020 Update_3-16-20 1100 am_clean.docx
Importance: High

JIC Clearance: Attached via HHS is an urgent review request for FDA testing guidance. **Response due to me at 1:50 PM.** This is for immediate effect and late responses may not be accepted. Please route to appropriate IMS taskforce and leadership

(b)(5)

Lauren

Lauren Hoffmann, MA, BS | Lead Public Health Analyst/Senior Issues Manager, Division of Issues Management, Analysis and Coordination (IMAC) | Office of Chief of Staff | Office of the Director | Centers for Disease Control and Prevention
1600 Clifton Road, NE, Mail Stop H21-10, Atlanta, GA 30329-4027 | Office: 404-639-7126 | Mobile: (b)(6) | E-mail: lhoffmann@cdc.gov.

From: Schuchat, Anne MD (CDC/OD)
Sent: 16 Mar 2020 17:16:23 +0000
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID); Monroe, Steve (CDC/DDPHSS/OLSS/OD)
Subject: FW: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Attachments: 20010-IIE-COVID-19-2020 Update_3-16-20 1100 am_clean.docx
Importance: High

From: Hoffmann, Lauren (CDC/OD/OCS) <cpf5@cdc.gov>
Sent: Monday, March 16, 2020 12:37 PM
To: CDC IMS JIC Emergency Clearance-2 <eocjicclear2@cdc.gov>; Ford, Kenya S. (CDC/OCOO/OGC) <kdf6@cdc.gov>; Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Cc: CDC Review Clear Coordinator <rcc@cdc.gov>; CDC Regulations <cdcregulations@cdc.gov>; Clark, Cynthia K. (CDC/OD/OCS) <cfc8@cdc.gov>; Caudwell, Kerry M. (CDC/OD/OCS) <cli9@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Campbell, Amanda (CDC/OD/OCS) <ons3@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>
Subject: HHS Clearance due 1:50 PM COVID-19 testing guidance (FDA)
Importance: High

JIC Clearance: Attached via HHS is an urgent review request for FDA testing guidance. **Response due to me at 1:50 PM.** This is for immediate effect and late responses may not be accepted. Please route to appropriate IMS taskforce and leadership

(b)(5)

Lauren

Lauren Hoffmann, MA, BS | Lead Public Health Analyst/Senior Issues Manager, Division of Issues Management, Analysis and Coordination (IMAC) | Office of Chief of Staff | Office of the Director | Centers for Disease Control and Prevention
1600 Clifton Road, NE, Mail Stop H21-10, Atlanta, GA 30329-4027 | Office: 404-639-7126 | Mobile: (b)(6) | E-mail: lhoffmann@cdc.gov.

